Radient's CEO will kick off Aegis Conference in Vegas Print E-mail
By M.E.Garza   
Thursday, 28 April 2011 03:11
As we told our premium susbcribers Wednesday morning, two of the companies we've been following have been invited to speak in front of hundreds of brokers and high net worth investors at the exclusive Aegis Capital Emerging Growth Conference which is taking place starting today in Vegas (at the Palazzo Hotel) between April 28 and April 30.

This is an important development for these two companies because the conference attracts a lot of market movers like floor brokers, institutional trading desk specialists and other opinion leaders. This is not your typical investors conference. It costs $6,000 just to get in the door. It's obvious that someone wants to hear more details about the developments at these two firms and that the buzz we've been hearing about these emerging penny plays is coming into play. Here is what we know:

Despite the pundits who keep predicting their demise without even speaking to management or grasping an understanding of the growth, significance and partnership opportunities surrounding their multi-platform, early cancer detection technology, the management team at Radient Pharmaceuticals (AMEX:RPC) has been busy turning their fortunes around since late 2010 and it seems few have been getting the story, much less getting it correct. We told our premium susbcribers yesterday that the company had been keeping a low profile working hard behind the scenes, but that things were about to change given this invitation to kick off the conference with a speech on Thursday night at Aegis. Shares of the company rose over +10.24% in regular session trading on this news Wednesday and then an additional +67% during after-hours trading after the company announced results of its analysis of data from the U.S. clinical trial of Onko-Sure® For Colorectal Cancer. More specific clinical trial data from the validation study is set to come in the form of peer-reviewed journals, as announced previously.

After re-structuring and cleaning up the huge debts that ran up during their lengthy FDA approval process for the Onko‐Sure® in vitro diagnostic (IVD) cancer test, the company has been preparing full commercialization efforts not only in the U.S. but also in various countries abroad. In addtion to all of their usual business, management has been setting the record straight about several key issues- including the validation study itself. As other investigations, including our own have proven, the validation study was designed and coordinated with clinicians at the Mayo Clinic.  A special investigator with ties to the SEC, a former NASDAQ listings compliance officer turned consultant and the very high profile law firm which Radient hired presented that evidence and more in the form of contractual and IRB backed study materials to various review board members at the NYSE Amex. Much of the damage to the company's reputation came after a tabloid columnist maliciously reported that the Mayo Clinic denied any link to Radient in an improperly filed (and later corrected) headline that was sent across newswires and shaved millions of dollars off Radient's market cap.

Sources tell BioMedReports that DLA Piper, the law firm retained to represent the RPC has set their sites on the individuals whose actions have caused the most harm to the firm's investors and business activities. One source, who spoke on condition of anonymity, made it clear that the completely unnecessary and costly headaches which have been caused are not being taken lightly by the legal team and other officials. According to the same source, some of those individuals have been put on notice in writing and/or face the possibility of legal action going forward. 

As if that weren't enough to cause the 5-6 million shorts in the stock some angst, it appears the other shoe is about to drop. Cash from the highly debated $10 million dollar order from the Indian Government's cancer screening program sold by Ministry of Health and Family Welfare approved distributor Gaur Diagno in India, is set to start coming in. The money, as specified in the sales contracts, will come in on a regular basis and company officials should document the key material event in official SEC filings.

The deal to bring RPC's cancer vaccine spin-of, Nuvax, public is all set and should be announced shortly as well. Since Radient shareholders will own a very big piece of that new company and will no-doubt benefit from the valuation once shares begin trading, this news development is a "no brainer" in terms of providing equity and return from the previously hidden cancer vaccine asset. 

After a very successful hearing with NYSE AMEX officials that has allowed the company to continue trading on the big boards, the sense we get from talking to other analysts and observers is that Radient is also set to start being more aggressive in their marketing and visibility efforts.

Short the stock? Our friendly advice would be to cover.

The kick-off speech at the Aegis Conference in Las Vegas by CEO, Douglas MacLellan should be very enlightening and we will certainly report what we hear.

The other company that has been invited to present is Tapimmune (OTC:TPIV). Shares of the company rose 5% during Wednesday's trading after our initial report to subscribers.

The relatively unknown stock has been trading more actively and we continue to anticipate the value of their shares to continue increasing, just as we've been saying since the stock was trading in the $.15 to $.18 range. As we told you before, the company is set to announce several key developments in the coming months and they have two programs under development with doctors at the Mayo Clinic. One of those programs involves a "game changing" application in the area of biodefense and infectious diseases (word on the street is that several government grant programs have taken notice and that there is some very active exploration of non-dillutive funding opportunities).

Tapimmune's other program is set to move into human clinical trials in breast cancer patients who have a form of breast cancer that express Her2/neu receptors (also called Her2/neu breast cancer).  Keith Knutson, M.D. of the Mayo Clinic will serve as Principal Investigator. 

While there are ongoing vaccine trials targeting Her2/neu. The major disadvantage of technologies that are currently in development are their inability to cover all or a majority of Her2/neu cancer patients and their ability for long-term protection. Some of them seem to be effective only in a subset of Her2/neu cancer patients. Along with Mayo the company believes this new technology could cover up to 90% of the Her2/neu patients and perhaps even last a life time. This would mark a significant improvement that could cover an additional 30% of the population who may not be covered by the other technologies that are currently in development (after some recent meetings with the FDA we are anticipating an NDA Filing shortly). Her2/neu receptor related cancer is a very aggressive form of breast cancer that affects a subset of breast cancer patients. Herceptin (a Her2/neu inhibitor by Genentech) is an approved drug with annual sales in excess of $4 Billion.

Those who follow the company closely, including some small cap investment funds, say that seeing TPIV shares slowly climbing back to previous highs of $1.50+ in the next few months is not out of the question, particularly given their very low float and positive news flow. We'll montior their presentation to those brokers and investors at Aegis and report back. In the meantime, you can learn about the company's technology platform by watching the video here or reading the article here.


Disclosure: Still long all of my shares of TPIV and RPC




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter